-
Mashup Score: 0
Patients with idiopathic pulmonary fibrosis had less lung function decline with an oral c-Jun N-terminal kinase 1, or JNK, inhibitor vs. placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.“This was supported by improvements in circulating biomarkers of fibrosis and a reduction in respiratory [adverse events] in the CC-90001 arms,”
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0
Patients with idiopathic pulmonary fibrosis had less lung function decline with an oral c-Jun N-terminal kinase 1, or JNK, inhibitor vs. placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.“This was supported by improvements in circulating biomarkers of fibrosis and a reduction in respiratory [adverse events] in the CC-90001 arms,”
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0
Among patients with idiopathic pulmonary fibrosis, lung function decline was comparable between 52-week zinpentraxin alfa treatment and placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.“Although well tolerated, no clinical benefit of zinpentraxin alfa over placebo was observed in the STARSCAPE trial in patients with IPF,” Luca
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0
Among patients with idiopathic pulmonary fibrosis, lung function decline was comparable between 52-week zinpentraxin alfa treatment and placebo, according to results published in American Journal of Respiratory and Critical Care Medicine.“Although well tolerated, no clinical benefit of zinpentraxin alfa over placebo was observed in the STARSCAPE trial in patients with IPF,” Luca
Source: www.healio.comCategories: General Medicine News, PulmonologyTweet
Published in #AJRCCM: Patients with idiopathic pulmonary fibrosis (#IPF) had less #lung function decline with an oral c-Jun N-terminal kinase 1, or JNK, inhibitor vs. placebo. @ATSBlueEditor Read more⬇️ https://t.co/Q1bvMyagZW